2.50
-0.24(-8.76%)
Currency In USD
| Previous Close | 2.74 |
| Open | 2.74 |
| Day High | 2.75 |
| Day Low | 2.47 |
| 52-Week High | 5.46 |
| 52-Week Low | 0.99 |
| Volume | 2.28M |
| Average Volume | 2.84M |
| Market Cap | 228.66M |
| PE | -0.92 |
| EPS | -2.71 |
| Moving Average 50 Days | 2.17 |
| Moving Average 200 Days | 1.86 |
| Change | -0.24 |
If you invested $1000 in Cabaletta Bio, Inc. (CABA) since IPO date, it would be worth $250 as of October 30, 2025 at a share price of $2.5. Whereas If you bought $1000 worth of Cabaletta Bio, Inc. (CABA) shares 5 years ago, it would be worth $216.08 as of October 30, 2025 at a share price of $2.5.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025
GlobeNewswire Inc.
Oct 27, 2025 11:00 AM GMT
– All myositis patients in the Phase 1/2 DM/ASyS cohort with sufficient follow-up who met key registrational inclusion criteria exceeded the registrational primary endpoint, demonstrating major TIS responses with no immunomodulators – – Myositis regi
Cabaletta Bio Announces Appointment of Steve Gavel as Chief Commercial Officer and Award of Inducement Grant
GlobeNewswire Inc.
Oct 14, 2025 12:00 PM GMT
– Gavel brings highly relevant CAR T experience from Legend Biotech where he led the launch and commercialization of CARVYKTI® from 2018 until 2025 – PHILADELPHIA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-sta
Cabaletta Bio Presents First Rese-cel Data with No Preconditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress
GlobeNewswire Inc.
Oct 09, 2025 4:00 PM GMT
– Complete B cell depletion, rapid reduction in autoantibodies and near-complete resolution of clinical symptoms in two of three refractory patients; all three patients remained off immunomodulators since infusion and are off or tapering steroids as